September 20, 2017 7:10pm
A revolt is underway, investors want more disclosure, governance and attention for the silence is deafening …
Managements need to reconcile their impulses to hide in the toilet … when investors want answers while they manipulate expectation as to performance!
Pre-open indications: 3 hits and 2 miss (JUNO is down -$1.82 or -4.04% after and offering announcement;
Out and about: Spark Therapeutics (ONCE) has entered into a licensing agreement with France based, Genethon for the development and commercialization of an adeno-associated viral gene therapy targeting the liver to address a rare genetic disease; JUNO Therapeutics (JUNO) proposes a $225 M follow-on offering
Three (3) of my five (5) “rocket man or women” CEO designations as to their current, sooner or later corporate implosions:
- Capricor (CAPR – Linda Marban) takes a big hit (-$0.30 to $1.95 after yesterday’s flash in the pan, expect more downside, last year (9/20/16) the share was trading at $3.76;
- Applied Genetic Technologies (AGTC – Sue Washer) gets whacked again (-$0.08 to $3.67), who or what will stem this downside; last year (9/20/16) the share was trading at $8.82;
- Biostage (BSTG – James McGorry) another “rocket man” was down (-$0.01 to $0.32), last year (9/20/16) the share was trading at $1.09;
I answer one question, in which company should investors commit and keep their money. In the grip of rotating cycles and disparaging trends, what is the price of sector knowledge – a subscription!
Members only. Please login.
